Evolent Health vs Rentokil Initial
EVH and RTO side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVH and RTO compare
Evolent Health scores higher on the StockData Score (7 against 0 for Rentokil Initial), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVH | RTO |
|---|---|---|
| Size and price | ||
| Market cap | $554M | – |
| Share price | $4.90 | $23.91 |
| Change, 1 year | 10.1% | −10.3% |
| Change, 5 years | −83.0% | −44.5% |
| Beta (5Y) | 0.82 | 0.96 |
| Employees | 4,200 | 59K |
| StockData Score | ||
| Total score | 7 (better) | 0 |
| Valuation score | 3 (better) | 0 |
| Growth score | 3 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× | – |
| P/B | 1.5× | – |
| Fair value | $6.93 | – |
| Margin of safety | 29.3% | – |
| Growth | ||
| Revenue growth (TTM) | 14.1% | – |
| Revenue growth, 5Y average | 15.2% | – |
| Profitability | ||
| Gross margin | 15.0% | – |
| Operating margin | −18.5% | – |
| Net margin | −21.7% | – |
| Return on equity | −83.6% | – |
| Return on invested capital | −23.0% | – |
| Financial health | ||
| Debt / equity | 2.60 | – |
| Interest coverage | −6.2× | – |
| Current ratio | 1.26 | – |
| Altman Z-score | −0.24 | – |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 99.3% | 3.1% |
| Held by insiders | 3.3% | 0.00% |
| Insider net buying, 12 months | −$329K | – |
| Short interest, % of float | 9.7% | – |
Go deeper
- EVH stock overview
- EVH income statement
- EVH valuation and score
- RTO stock overview
- RTO income statement
- RTO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.